Dupuytren's contracture is a condition in which there is difficulty in articulating the fingers of the hand due to formation of tissue knots beneath the skin. The fingers become permanently bent in a flexed position in severe condition. Dupuytren's contracture is not painful and most commonly affects the ring finger followed by the little and middle fingers. It has a higher rate in males over the age of 50. The exact causes of Dupuytren's contracture are unknown, however, the risk factors include thyroid problems, alcoholism, liver disease, smoking, diabetes, epilepsy, previous hand trauma, and family history. The surgery is performed when the proximal interphalangeal joint contracture exceeds 20 degrees or the metacarpophalangeal joint contracture exceeds 40 degrees. The less severe forms of the Dupuytren's contracture disease are treated with steroid treatment and physiotherapy.
COVID-19 Impact Analysis
COVID-19 is an infectious disease that originated in Hubei province of the Wuhan city in China in late December. The highly contagious disease, caused by a virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is transmitted from human to human. Since the outbreak in December 2019, the disease has spread to almost 213 countries around the globe with the World Health Organization declaring it a public health emergency on March 11, 2020.
Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing shortage of these drugs. Thus, the pharmaceutical and biotechnology industries are expected witness a significant growth in the future owing to the demand for vaccine and treatment drugs for COVID-19. This, in turn, is expected to have a significant impact on the Dupuytren’s contracture market.
Top Impacting Factors
Increase in geriatric population leading to rise in patient population is the key driver of the global Dupuytren’s contracture market. In addition, rise in cardiac cases such as heart attack, other factors includes cancer, kidney failure, end-stage lung cancer, and hypothyroidism boosts the market growth. Moreover, rise in screening and increase in healthcare expenditure propel the growth of the Dupuytren’s contracture market.
In addition, rise in awareness about health and government initiatives to improve healthcare infrastructure are some factors that boosts the market growth. Moreover, increase in awareness about cardiac diseases can propel the growth of the market.
Furthermore, ongoing research & developments for creating efficient and availability of cost-effective treatments boosts the market growth.
However, complications and risk associated with Dupuytren’s contracture surgery and invasive nature of the treatment restrain the growth of the market.
Market Trends
New Product Launches to Flourish the Market
In September 2019, Endo International Plc. announced four new studies of XIAFLEX (collagenase clostridium histolyticum), including real-world data, for the treatment of Dupuytren's contracture. XIAFLEX is indicated for the treatment of adult patients with Dupuytren's contracture with a palpable cord.
In April 2018, Paladin Labs Inc. announced the launch of a new indication for XIAFLEX (collagenase clostridium histolyticum), the first and only Health Canada-approved treatment for appropriate patients with peyronie's disease with palpable plaque and curvature deformity of at least 30 degrees at the start.
Key Benefits of the Report
- This study presents the analytical depiction of the Dupuytren’s contracture market industry along with the current trends and future estimations to determine the imminent investment pockets.
- The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the market share.
- The current market is quantitatively analyzed to highlight the market growth scenario.
- Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
- The report provides a detailed market analysis depending on competitive intensity and how the competition will take shape in coming years.
Questions Answered in the Dupuytren’s Contracture Market Report
- Which are the leading players active in the Dupuytren’s contracture market?
- What are the current trends that will influence the market in the next few years?
- What are the driving factors, restraints, and opportunities of the market?
- What future projections would help in taking further strategic steps?
- What is Dupuytren’s contracture market?
- What is Dupuytren’s contracture market prediction in the future?
- Who are the leading global players in the Dupuytren’s contracture market?
- What are the current trends and predicted trends?
- What are the key benefits of the Dupuytren’s contracture market report?
Dupuytren’s Contracture Market Report Highlights
| Aspects | Details |
 By Type |
|
 By Diagnosis |
|
 By End User |
|
 By Region |
|
 Key Market Players | Bristol-Meyers Squibb Co., Pfizer Inc., Merck Sharp & Dohme Corp., West-Ward Pharmaceuticals, Endo International plc., Nantong Jinghua Pharmaceutical Co., Ltd., Actiza Pharmaceutical Private Limited, Spear Pharmacueticals, Fresenius Kabi AG |
Loading Table Of Content...
